Latest News

Medscape Education

The Atopic Dermatitis Learning Center: Riding the Next Wave

Atopic dermatitis (AD) is a chronic inflammatory skin disorder that affects 5% to 30% of children and 1% to 10% of adults globally. It is characterized by recurrent eczematous lesions and intense itch and can have a severe impact on quality of life. Numerous agents that target the immunological mechanism of AD are under investigation in pediatric and adult patients. It is imperative that clinicians have the most recent data to provide optimal outcomes for their patients with AD.

Learn More

IEC Statement on New COVID 19 Vaccines

IEC has issued a position statement on COVID 19 Vaccines and Atopic Dermatitis to address concerns about potential risks associated with these novel vaccinations.

More Details

Read the latest IEC articles, published in JAAD International, British Journal of Dermatology and The Journal of Allergy and Clinical Immunology.  

Therapeutic education in atopic dermatitis: A position paper from the International Eczema Council Eichenfield L, Kusari A, Han A, Marcoux D, Nosbaum A, Stalder JF, Barbarot S, Deleuran, M, Lio P (2021). JAAD International 

Priority research questions in atopic dermatitis: An International Eczema Council eDelphi consensus. Abuabara K, Nicholls S., Langan S, Guttman‐Yassky E, Reynolds N, Paller A, Brown S (2021). British Journal of Dermatology. Accepted Author Manuscript.

Biomarkers in atopic dermatitis - a review on behalf of the International Eczema Council. Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, Hijnen D, Guttman-Yassky E. [published online ahead of print, 2021 Jan 28]. The Journal of Allergy and Clinical Immunology. 2021;S0091-6749(21)00096-8. doi:10.1016/j.jaci.2021.01.013

For all IEC publications, see our expanded list.



IEC Webcasts Available

Webcasts of IEC symposia on "Biomarkers" are now available on-demand.

More Details

NEA Presents Eczema Expo 2020

The National Eczema Association will be holding its Eczema Expo 2020 virtually this year.

For further details, see


Coronavirus SECURE-AD Registry

SECURE-AD (Surveillance Epidemiology of Corona Virus (COVID-19) Under Research Exclusion – Atopic Dermatitis; is a secure, online, de-identified international reporting registry for health care providers to report outcomes of COVID-19 in AD patients who have been Covid-19 infected or where such an infection has been strongly suspected. 

More Details

IEC Statement on COVID 19

IEC would like to provide guidance on the use of systemic treatments for atopic dermatitis (AD; commonly called eczema) in the context of the COVID-19 pandemic, based on currently available pandemic and pharmacologic information.

More Details
Page 1 of 2